SEATTLE--(BUSINESS WIRE)-- Receptor Life Sciences (RLS) today announced the acceptance of two posters for presentation at the Respiratory Drug Delivery (RDD 2021) conference. The posters report Cannabidiol (CBD) pharmacokinetics in healthy volunteers following inhalation of RLS103, an investigational inhaled dry powder CBD. RLS103 is being developed for the treatment of acute panic attack in panic disorder and performance anxiety in social anxiety disorder (SAD).

This pharmacokinetic study demonstrated that RLS103 facilitates immediate CBD delivery to the bloodstream with peak concentrations at 3.8 minutes that are 71-fold greater than oral CBD on a dose-adjusted basis. The overall systemic exposure, adjusted for dose, was 9-fold greater than that following oral administration because inhalation delivery bypasses hepatic first-pass metabolism. RLS103 delivered CBD with an efficiency 7-fold greater than a vaporizer.

“No immediate-acting treatments for these conditions are currently available, so an inhaled CBD, like RLS103, with an ultra-rapid onset, has the potential to address this need in both disorders,” said Andrea Leone-Bay, PhD, Founder and Chief Scientific Officer of Receptor Life Sciences. RLS103 is a drug-device combination product based on the Technosphere^® dry powder inhalation system licensed from MannKind Corporation.

RDD 2021 is the premier international conference for scientists and drug developers focused on pulmonary and nasal drug delivery. This year, RDD is a virtual conference and Receptor’s poster presentations can be viewed online by conference participants between April 27 and June 20.

• “Using Inhalation to Bypass First-Pass Metabolism as a Means of Improving Cannabidiol Bioavailability,” Kelly S. Kraft, Orrin Devinsky, Lorraine Rusch, Melanie Fein, and Andrea Leone-Bay; and
• “An Indirect Pharmacokinetic Comparison of Cannabidiol Formulations: Dry Power Inhaled (DPI) vs Vaporization,” Andrea Leone-Bay, Orrin Devinsky, Lorraine Rusch, Melanie Fein, and Kelly S. Kraft.

Panic disorder affects about 5.4 million adults in the United States, according to the National Institute of Mental Health. Social Anxiety Disorder affects about 15 million adults in the U.S. and is the second-most commonly diagnosed anxiety disorder (https://adaa.org/understanding-anxiety/social-anxiety-disorder).

About Receptor Life Sciences

Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval see www.receptorlife.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005113/en/